Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0250 -0.0030 (-10.71%)
Streaming Delayed Price Updated: 3:38 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Highlights Data in Multiple Presentations at EASD
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Oversubscribed $175 Million Private Placement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Full Year 2024 Operating and Financial Results
SAB-142 Phase 1 trial positive topline data announced at KOL event 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>